In the Media

Connect with Lyme

In the Media

10/07/2021

Flightpath Licenses the First Antibiotic that Selectively Kills Lyme Disease Spirochetes

Since 2018, Project Lyme has granted over $1 million to Bay Area Lyme Foundation to support their rigorous scientific agenda. Project Lyme is excited to have contributed to many multi-year research projects which Bay Area Lyme manages. A portion of the money Project Lyme raised at our 2020 Gala was used to fund a recent study with Flightpath Biosciences, Inc. Yesterday, they announced a newly licensed antibiotic that selectively kills Lyme Disease spirochetes. They are developing a narrow-spectrum antimicrobial therapeutic that can kill the bacteria causing Lyme disease without destroying the gut microbiome or contributing to the global Antimicrobial Resistance problem which has been associated with increased risk of chronic diseases.

In the Media

09/17/2021

What Lurks in the Woods

Life was going well for Nicole Bell and her husband Russ, both successful engineers and entrepreneurs… until Russ started experiencing symptoms of cognitive decline. They visited doctor after doctor and were told it was Alzheimer’s disease, but the root cause turned out to be something they never expected—tick-borne disease. In her soon-to-be-released memoir What Lurks in the Woods (October 2021), Nicole describes her harrowing investigation into her husband’s mysterious illness in hopes that it will help others who are dealing with bizarre chronic symptoms to find the cause before it’s too late. Nicole graciously sat down for a (virtual) interview with Project Lyme about her book and her heartfelt message to the chronic illness community.

In the Media

06/09/2021

Gillibrand Pushes For Increased Funding For Lyme Disease And Tick-Borne Illness Research

“When I became severely ill in 2010, it took ten doctors and multiple false negative test results before being diagnosed with Lyme disease and the co-infection babesia,” said New York advocate and Project Lyme Executive Committee Chairman David Roth. “There are enormous gaps in our understanding of the pathology of these diseases and their treatment, and there is a tremendous need for better diagnostic tests. I want to thank Senator Gillibrand for her leadership on this issue and for consistently fighting for increased funding for research of these diseases.”